Eli Lilly collaborates with Immunocore on immunotherapy combo; Actelion, Max Planck launch Vaxxilon;

@FierceBiotech: Facing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story | Follow @FierceBiotech

@JohnCFierce: These guys at Spinifex are smart--Giant Novartis downs a pain med in $200M-plus buyout of tiny Spinifex. More | Follow @JohnCFierce

@DamianFierce: From BIO last week, here's $QURE CEO Aldag talking about $CLDN, $AAVL and the future of gene therapy. Listen | Follow @DamianFierce

> Eli Lilly ($LLY) and Immunocore have forged an immunotherapy-based clinical trial collaboration to explore the use of Immunocore's lead T-cell receptor-based therapeutic IMCgp100 in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma. Release

> Switzerland's Actelion and the Max Planck Society have spun off a new biotech called Vaxxilon to advance synthetic carbohydrate vaccines. Release

> Immune Pharmaceuticals has struck a deal with Yissum, the tech transfer operation of Hebrew University of Jerusalem, to license certain of Yissum's patents for the development and commercialization of a topical nano-formulated version of AmiKet. Release

Medical Device News

@FierceMedDev: ICYMI: FDA gives nod to newest pelvic mesh product, despite ongoing safety issues. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Bard VP touts new study of its Lutonix drug-coated balloon to fight PAD. Article | Follow @VarunSaxena2

@EmilyWFierce: EU stands by crackdown on drug spending in Ireland. FiercePharma story | Follow @EmilyWFierce

> Former OtisMed CEO sentenced to two years in prison for shipping device after FDA rejected it. Article

> Olympus faces new suit from UCLA superbug patient over duodenoscope deviceFacing off rivals, Merck looks to expand CINV label on positive PhIII Emend study. Story

> Wearable, badge-based hand-washing monitoring system improves hospital staff compliance. Report

Pharma News

@FiercePharma: Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. FiercePharmaMarketing item | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: France's TxCell closes its plant at ANSM urging to avoid contamination. Story | Follow @EricPFierce

@CarlyHFierce: Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More | Follow @CarlyHFierce

> Will Mylan boost its Perrigo bid? New securities filing suggests it won't. More

> Tougher regulations force Indian drugmakers to invest or divest. Article

Animal Health News

> Egg prices soar, menu items dropped in wake of historic avian flu. More

> Investors erase Zoetis gains as questions emerge about Valeant's pursuit. Report

> Sorrento nabs key FDA designation for nonopiate drug to treat bone pain in dogs. Item

> Scottish scientists design piglets to resist African swine fever. Story

> Henry Schein expands global reach, taking majority stake in Denmark's Kruuse. Article

Biotech IT News

> Eisai strikes extensive multiyear IT outsourcing deal with Accenture. News

> Google steps up wearables plan with clinical trial-focused wristband. Story

> Analyst: R&D time pressures mean clinical trial tech and automation are finally taking off. More

> Google to pair its cloud-computing power with Broad's analytic tools. Article

> SEC starts pursuit of biotech-focused hacking ring. Report

Pharma Marketing News

> Novartis shells out $200M-plus for Spinifex and its mid-stage pain drug. News

> Should Bristol-Myers cut payer deals to boost melanoma combo over one-drug treatments? More

> Will pharma jump into an EHR app store near you? Don't count on it anytime soon. Story

> Nuedexta maker Avanir taps actor Danny Glover to shed light on little-known neurological condition. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.